A Day in the Life: Consults with a Rheumatology Fellow

Save

Join medical resident Siobhan Deshauer, MD, as she visits three hospitals for inpatient rheumatology.

Can You Reduce Frequency of Methotrexate Monitoring?

Save

Observational research presented at the British Society for Rheumatology meeting suggest that, based on the COVID-19 pandemic experience, reduced frequency of routine lab monitoring in patients receiving weekly methotrexate therapy for rheumatoid arthritis (RA) was not associated with an increase in adverse outcomes.

Wiki Guidelines Approach to Pyogenic Osteomyelitis

Save

A crowd sourced, WikiGuidelines approach to clinical treatment guideline development for pyogenic osteomyelitis yielded 7 important clinical questions, 2 clear treatment recommendations and 5 topic reviews to inform future treatment or investigations.

Bimekizumab's Favorable Safety Profile in Psoriasis

Save

A 2-year safety study of bimekizumab, the dual IL-17A/F inhibitor, plaque psoriasis patients showed bimekizumab (BMK), to be effective, well tolerated, with no new safety concerns other than a modest risk of oral candidiasis.

ASCORE: Seropositivity Favors Abatacept Drug Survival

Save

The ASCORE (Abatacept SubCutaneOus in Routine clinical practicE) study evaluated efficacy, safety, and drug retention (durability) of abatacept (ABA) moderate-to-severe rheumatoid arthritis (RA) and found consistently better ABA durability in those who were seropositive. 

Making You the Expert of You! (Smart Rules for Patients)

Save

You’ve scheduled an appointment with your medical provider - how do you make the most of it? We've gathered these tips and suggestions to share with patients.

Polygenic Risk Scores to Identfy Severe Knee and Hip Osteoarthritis

Save

Prevention of knee and hip osteoarthritis would obviate considerable disability and future surgery.  We may be one step closer according to a prospective European GWAS study showing polygenic risk scores (PRSs) significantly associated with higher risks for knee and hip OA joint replacement.

Diagnostic Delays in Spondyloarthritis Still Prolonged

Save

Previously quoted average  delay in diagnosing axial spondyloarthritis (axSpA) may be improving as a recent UK study shows the mean average time to diagnosis in two different NHS trusts was between five and six years. 

Efficacy of Subsequent b/tsDMARD Use in Rheumatoid Arthritis

Save

Analysis of rheumatoid arthritis (RA) data from the British Society for Rheumatology Biologics Register shows that, even after failing three or more biologic or targeted synthetic DMARDs (b/tsDMARDs), patients may continue to benefit from repeated trials of unused b/tsDMARDs. 

Allopurinol Use Does Not Increase Mortality in Gout with Chronic Kidney Disease

Save

A population based trial has shown that allopurinol use dose escalation and achieving target uric acid levels (with allopurinol), was not associated with increased mortality in patients with gout and concurrent CKD

Trends in Rheumatoid Arthritis Disabililty, Despite Biologics

Save

Disability claims in the U.S. related to rheumatoid arthritis (RA) were just as common in 2015 as in 1999, a government researcher found, against expectations that the advent of biologic therapy would have led to a steady decrease.

Upadacitinib FDA Approved for Ankylosing Spondylitis

Save

Abbvie has announced the US Food and Drug Administration has approved upadacitinib (Rinvoq or UPA) for use in adults with active ankylosing spondylitis, who have not responded or been intolerant of one or more TNF blockers. The recommended dose is 15 mg per day.

Prolonged TNF Inhibitor Use Delays Sacroiliac Progression

Save

While tumour necrosis factor inhibitors (TNFi) have been shown to alter/retard X-ray outcomes in peripheral inflammatory arthritis, the inhibitor effects of TNFi on axial skeletal progression in spondylitis has been difficult to prove, owing to difficulties in study design, identifying best cohorts and a presumed slower rate of change in the spine. 

PsA Journal Club - Fecal Transplant & H2H IXE vs ADA

Save

Playback now available! Watch our Tuesday Nite Rheumatology, held April 26th, 2022, which featured a Journal Club panel discussion  about two important studies.

Biologics for JIA? Not So Fast, Say Insurers

Save

It's not a simple matter to prescribe tumor necrosis factor (TNF) inhibitors for patients with juvenile idiopathic arthritis (JIA), at least those with insurance, a single-center study found.

Arthritis Predicts Hepatic Fibrosis in Hemochromatosis

Save

Mayo Clinic Proceedings reports the results of a retrospective, cross-sectional of patients with HFE hemochromatosis showing that advanced hepatic fibrosis is primarily seen in those with arthritis due to HFE hemochromatosis. 

COVID-19 Vaccination Uptake and Perceptions in Rheumatic Patients

Save

Putman et al has reported vaccine survey results from the COVID-19 Global Rheumatology Alliance (C19-GRA) in Lancet Rheumatology showing the uptake and vaccine hesitancy among people with rheumatic diseases (RMD).

Survey data from 7005 vaccinated and unvaccinated, adult RMD respondents from 102 countries was analyzed.

Evusheld as Protective Therapy in High Risk COVID-19 Patients

Save

A single dose of the monoclonal-antibody AZD7442 (combination of tixagevimab and cilgavimab) has been shown to be safe and effective as prophylaxis against COVID-19 infection in high risk individuals who tested positive for COVID-19. 

TNR - Controversies in PsA

Save

Held on April 19, 2022, Tuesday Night Rheumatology: Controversies in PsA, featured a lively and informative panel discussion, moderated by Dr. Jack Cush.

The PsA Expert panelists included:

Faith in Exercise Benefit Boosts Actual Benefit in SpA

Save

Patients with axial spondyloarthritis (SpA) got more bang for their exercise buck in a randomized trial when they had good opinions about their workout program, with better persistence with exercise at 1 year relative to a control group, researchers said.